Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

Fig. 1

Schematic diagram of health status for cost analysis. DPP-4i dipeptidyl peptidase-4 inhibitors, hHF hospitalization for heart failure, DM w HF diabetes mellitus with heart failure, DM w/o HF diabetes mellitus without heart failure, HF death death after diagnosis of heart failure, other death death without diagnosis of heart failure

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840